Anti-Fertility Activity of Montelukast in Female Albino Wistar Rats by Herald Samuel Yesubalan, K
  
ANTI-FERTILITY ACTIVITY  OF MONTELUKAST IN FEMALE 
ALBINO WISTAR RATS 
 
A dissertation submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY 
CHENNAI- 600 032. 
           In partial fulfillment of the requirements for the award of Degree of 
MASTER OF PHARMACY 
IN 
PHARMACOLOGY 
Submitted  
By 
HERALD SAMUEL YESUBALAN K 
(Reg No: 261325953) 
                                         Under the guidance of 
Dr.D.Prabu, M.Pharm.,Ph.D., 
 
 
DEPARTMENT OF PHARMACOLOGY 
EDAYATHANGUDY.G.S PILLAY COLLEGE OF PHARMACY 
NAGAPATTINAM-611002 
OCTOBER  2015 
  
ANTI-FERTILITY ACTIVITY  OF MONTELUKAST IN FEMALE 
ALBINO WISTAR RATS 
 
A dissertation submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY 
CHENNAI- 600 032. 
           In partial fulfillment of the requirements for the award of Degree of 
MASTER OF PHARMACY 
IN 
PHARMACOLOGY 
Submitted  
By 
Reg No: 261325953 
                                         Under the guidance of 
Dr.D.Prabu, M.Pharm.,Ph.D., 
 
 
DEPARTMENT OF PHARMACOLOGY 
EDAYATHANGUDY.G.S PILLAY COLLEGE OF PHARMACY 
NAGAPATTINAM-611002 
OCTOBER  2015 
  
 
Dr.D.Prabu, M.Pharm.,Ph.D., 
Professor, 
Department of Pharmacology 
Edayathangudy.G.S.Pillay College of Pharmacy, 
Nagapattinam. 
 
CERTIFICATE 
 
This is to certify  that the  dissertation entitled “ANTI-
FERTILITY ACTIVITY  OF MONTELUKAST IN FEMALE 
ALBINO WISTAR RATS” submitted by HERALD SAMUEL 
YESUBALAN K (Reg No: 261325953) in partial fulfillment for the award 
of degree of Master of Pharmacy to the Tamilnadu Dr. M.G.R Medical 
University, Chennai is an independent bonafide work of the candidate 
carried out under my guidance in the Department of Pharmacology, 
Edayathangudy.G.S.Pillay College of Pharmacy during the academic year 
2014-2015.   
 
Place: Nagapattinam                         
Dr.D.Prabu, M.Pharm.,Ph.D., 
 Date: 
 
 
 
 
  
Prof.Dr.D.Babu Ananth,M.Pharm.,Ph.D., 
Principal, 
Edayathangudy.G.S.Pillay College of Pharmacy,  
Nagapattinam – 611 002. 
            
                              
                            CERTIFICATE 
     
           This is to certify  that the  dissertation entitled “ANTI-
FERTILITY ACTIVITY  OF MONTELUKAST IN FEMALE 
ALBINO WISTAR RATS” submitted by HERALD SAMUEL 
YESUBALAN K (Reg No: 261325953)  in partial fulfillment for the 
award of degree of Master of Pharmacy to the Tamilnadu Dr. M.G.R 
Medical University, Chennai is an independent bonafide work of the 
candidate carried out under the guidance of  Dr.D.Prabu, 
M.Pharm.,Ph.D.,Professor, Department of Pharmacology, 
Edayathangudy.G.SPillay College of Pharmacy during the academic year 
2014-2015.   
 
Place: Nagapattinam       
Date:                                        
 Prof.Dr.D.Babu Ananth,M.Pharm., Ph.D., 
 
 
 
  
 
                       ACKNOWLEDGEMENT 
  
 I would like to express profound gratitude to Jothimani Chevalier 
Thiru.G.S.Pillay, Chairman, E.G.S.Pillay College of Pharmacy, and 
Thiru.S.Paramesvaran, M.Com., FCCA.,Secretary, E.G.S.Pillay College 
of Pharmacy. 
 I express my sincere and deep sense of gratitude to my guide 
Dr.D.Prabu, M.Pharm.,Ph.D.,Professor, Department of Pharmaceutical 
Analysis, Edayathangudy.G.S.Pillay College of Pharmacy,  for his 
invaluable and extreme support, encouragement, and co-operation 
throughout the course of my work. 
 I express my sincere gratitude to Prof. Dr.D.Babu 
Ananth,M.Pharm,Ph.D., Principal, E.G.S.Pillay College of Pharmacy, 
for his encouragement throughout the course of my work. 
 I express my sincere gratitude to Prof. Dr.M.Murugan, M.Pharm., 
Ph.D.,Director cum Professor, Head, Department of Pharmaceutics. 
E.G.S.Pillay College of Pharmacy, for his encouragement throughout the 
course of my work. 
 I  wish  to  express  my  great  thanks  to Prof.K.Shahul Hameed 
Maraicar , M.Pharm., (Ph.D), Director  cum Professor , Department     of 
Pharmaceutics, E.G.S.Pillay College of Pharmacy, for his support and   
valuable guidance during my project work. 
 I would like to extend my thanks to  all the Teaching  Staff and 
Non Teaching Staff, who are all supported me for the successful 
completion of my project work.        
 Last but not least, I express my deep sense of gratitude to my 
parents, family members and friends for their constant valuable blessings 
and kindness. 
  
INDEX 
 
CHAPT
ER NO. 
CONTENTS PAGE NO. 
1 INTRODUCTION 1 
2 
2.1 
2.1.1 
2.1.2 
2.2 
2.3 
2.4 
2.4.1 
2.4.2 
2.4.3 
2.5 
2.5.1 
2.5.2 
2.6 
 
2.7 
REVIEW OF LITERATURE 
Available methods of contraception 
Hormonal contraceptives 
Abortifacients 
The physiology of female reproductive system 
Female hormonal system 
 Estrogens 
Physiology of estrogens: 
Mechanism of action of estrogen 
The important biological activities of estrogen 
Ovarian cycle 
Ovulation 
Initiation of ovulation 
The corpus luteum – The “Lueteal” phase of the 
ovarian cycle 
Role of sperms in fertilization 
4 
4 
4 
5 
6 
6 
7 
7 
8 
8 
9 
9 
10 
10 
 
11 
  
2.8 
2.9 
2.10 
2.11 
2.12 
2.13 
2.14 
2.15 
2.15.1 
2.15.2 
2.15.3 
2.15.4 
2.16 
2.17 
2.18 
2.19 
2.20 
2.21 
 
Mechanism of steroid hormone action 
Arachidonic acid pathway 
Biosynthesis of leukotrienes 
Distribution of leukotrienes 
Leukotriene receptors  
Leukotrienes in the uterus: 
Drug profile  
Various stages of the estrus cycle in rats 
Proestrus 
Estrus 
Metestrus 
Diestrus 
The experimental procedure for taking vaginal 
smears 
Role of leukotriene in reproduction 
Role of leukotriene in ovulation 
Role of leukotriene in pregnancy 
Role of leukotriene in fertilization 
Role of leukotriene in implantation 
12 
13 
15 
16 
17 
19 
20 
23 
23 
23 
23 
23 
24 
24 
24 
25 
28 
28 
 
3 OBJECTIVES 29 
  
4 
4.1 
4.2 
4.3 
4.4 
4.5 
4.6 
4.7 
MATERIALS AND METHODS 
Animals 
Drugs 
Chemicals 
Instruments 
Anti-implantation activity 
Procedure for laparotomy 
Statistical analysis 
30 
30 
30 
30 
30 
31 
32 
33 
5 
5.1 
5.1.1 
 
5.1.2 
 
RESULTS 
The Effect of Montelukast on Implantation 
Anti-implantation activity of montelukast when 
treated with 1-7 days of pregnancy 
Anti-implantation activity of montelukast when 
treated with 7-21 days of pregnancy 
34 
34 
34 
 
37 
6 DISCUSSION 40 
7 CONCLUSION 49 
8 REFERENCES 50 
9 ANNEXURE 58 
 
 
1 
 
CHAPTER-1 
INTRODUCTION 
Anti-fertility agents are the agents, which prevents fertility by 
interfering with various normal reproductive mechanisms, in both males and 
females. Development of newer methods/agents for fertility control and 
research in this direction are imperative particularly the developing nations. If 
an ideal contraceptive were available, that contraceptive would be 100% 
effective, safe and easy to use; its effect would be reversible.1  
The world population explosion has pointed out the need for new, 
effective, and safe contraceptive agents or methods for maximum protection.  
Side effects of synthetics on normal and natural human body are much more 
aggressive and unpredictable at prolonged use as long as one which gender 
expects to use them. Now time is alarming us to think us some alternative in 
the field of contraception.2 
     India within, few years of time span will be the leading country as far 
as the population growth is concerned. Since the population rising 
tremendously, this may affect drastically the economic growth of India. Family 
planning has been promoted through several methods of contraception, but due 
to side effect produced by the use steroidal contraceptive and use of 
abortifaciant drugs. There is a need of drug which is effective with lesser side 
effects.3 
Approximately 48.2% of couples of 15 to 49 years of age practice 
family planning methods in India. Female sterilization accounts for 34.2%, 
with male sterilization declining from 3.4% in 1992–93 to 1.9% in 1998–99. 
Use of the condom increased to 3.1% from 2.4%. There is an urgent need for 
research to develop new contraceptive modalities especially for men and also 
for women and to make existing methods more safe, affordable and 
acceptable.4 
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 Arachidonic acid, a fatty acid synthesized from dietary linoleic acid, 
metabolizes in the body by cyclooxygenase (COX) and lipoxygenase (LOX) 
pathways. Metabolites of arachidonic acid are called eicosanoids. The COX 
pathway leads to prostaglandin and thrombaxane production and the LOX 
pathway leads to the leukotrienes and hydroxyeicosatetraenoic acids.5 The 
leukotrienes (LTs) are 5-lipoxygenase metabolites of arachidonic acid. The 
synthesis and release of (LTs) have been demonstrated in many cells and 
organs and LTs are considered to be normal product of continuous metabolism 
of arachidonic acid.6  
             Montelukast, a selective reversible cysteinyl leukotriene D4-receptor 
(LTD4 receptor) antagonist is currently available in the market for the treatment 
of asthma. It was found to have the gastro protective and antioxidant effects on 
indomethacin-induced gastric ulcer in rats,7 prophylactic potential against mild 
colitis induced by dextran sulphate sodium in rats8 and protective effect on 
smoking induced lung injury in Wistar rats.9      
The lipoxygenase products (leukotrienes) have been demonstrated in 
many mammalian tissues including humans. They are widely distributed in the 
lungs, gut, uterus, kidneys, skin, heart and the liver. Their roles as mediators of 
inflammation have made them therapeutic targets. The potential use of 
lipoxygenase products in the management of primary dysmenorrhoea 
(especially in patients who are not responding to the traditional treatment using 
PG synthetase inhibitors) and possibly also in cases of endometriosis.10 
The concentrations of PGE, PGF, LTB and LTC4/D/E increase in the 
ovary of PMSG-primed immature rats after the ovulatory process has been 
initiated by hCG administration. Since differences in the patterns of temporal 
changes of the various eicosanoids during ovulation are seen, we suggest that 
each eicosanoid plays a distinct role in the process of follicular rupture.11 
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Pharmacological inhibition of an alternative lipoxygenase (LOX) 
pathway has been shown to cause defective ovulation. The expression of 
ALOX5 and ALOX12 in the preovulatory follicle and that inhibiting the early 
phase LOX activity led to reduction in preovulatory PTGS2 induction and 
PGE2 production and thus defective ovulation. These findings may help to 
understand the mechanism for the involvement of the LOX pathway in LH-
triggered ovulatory response, at least the induction of PTGS2 activity, in rats.12 
LTB4 may play a role in the ovulatory pathways of the rat ovary and that LTB4 
may carry out its effects via MMP-2.13   
NDGA appears to be an inhibitor of ovulation in the rat. LTB 4 reversed 
the ovulation inhibition by NDGA, suggesting a role of this LT in intraovarian 
ovulatory changes. 14  
LTs in uterine functions during implantation processes and 
decidualization has been reported.15, 16 The presence of the lipoxygenase 
pathways in the pre-implantation rabbit uterus and blastocyst, their differential 
operation in various compartments of the uterus on various days of early 
pregnancy suggests an integrated role for these mediators in embryo-uterine 
interaction during implantation.17 Mouse and human spermatozoa require 
cysteinyl leukotriene activity for both fertilization and oocyte penetration.18  
Lipoxygenase metabolites may be involved in human parturition. Role 
for 5-LOX and FLAP in the control of parturition at term, and also suggest an 
involvement earlier in pregnancy.19 HSD11B2 in human placental trophoblasts 
is decreased by progesterone and increased by inhibition of endogenous LOX 
metabolites, and that a component of the effect of LOX metabolites on 
HSD11B2 is mediated by their stimulation of endogenous progesterone 
output.20 LTs are required for the induction and progression of 
decidualization.21 
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All above literatures proved that leukotrienes are involved in normal 
reproduction. If these leukotrienes are blocked or their receptor are blocked it 
may produce negative effect in reproduction. Based on this hypothesis in this 
study we have evaluated anti-implantation activity of montelukast a cysteinyl 
leukotriene receptor antagonist in female albino Wistar rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
CHAPTER-2 
LITERATURE REVIEW 
           Anti-fertility agents are the agents, which prevents fertility by 
interfering with various normal reproductive mechanisms, in both males and 
females. Development of newer methods/agents for fertility control and 
research in this direction are imperative particularly the developing nations. If 
an ideal contraceptive were available, that contraceptive would be 100% 
effective, safe and easy to use; its effect would be reversible. It should be 
aesthetically and personally acceptable in a variety of social, political and 
religious setting. It would be suitable culturally in terms of local attitudes 
concerning sexuality, reproduction; menstruation and the roles and 
responsibilities of men and women, and it would be applicable in terms of the 
health status of widely differing populations. It would be affordable, readily 
available and legal. Finally it would be appropriate for use at all stages of 
reproduction.1 
2.1     Available methods of contraception: 
        In the earlier part of present century, methods of contraception used 
(condoms, diaphragm, spermicidal creams, foam tablets etc.) were intimately 
related to sexual intercourse, therefore, despised by most couples and they also 
have higher failure rate. Hence hormonal contraceptives are widely used, with 
100% confidence and complete return to fertility on discontinuation.22 
The most widely used methods of contraception are.22, 23 
2.1.1 Hormonal contraceptives 
a. Oral contraceptives 
                1. Combined pill 
                2. Phase regimens 
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                3. Minipill (luteal supplement) 
                4. Post coital (emergency contraception) 
         b. Injectable contraceptives 
         c. Implants 
2.1.2 Abortifacients 
               a. Anti-progesterone (mifepristone or RU486) 
               b. Prostaglandins 
                 The control of fertility is frequent concern of women and health care 
providers the world over. Unfortunately there are still no 100% safe and 
effective contraceptive methods besides complete abstinence. One reason why 
some women may be reluctant to take oral contraceptives consistently and 
correctly is a fear of possible adverse effects listed below. 23, 24, 25 
Cardiovascular disease: Myocardial infraction, stroke, hypertension, venous 
thromboembolism, cerebrovascular insults, raise in HDL/LD ratio and high 
blood pressure. 
Cancer: Uterine cancer, ovarian cancer, endometrial cancer, breast cancer, 
cervical cancer, hepatoma, focal nodular hyperplasias, liver cell adenoma, 
hepatocellular cancer and genital carcinoma. 
Metabolic and endocrine effects: Diabetes or impaired glucose tolerance, gall 
stone and cholecystitis. 
Down-regulating bone metabolism.  
Others: Nausea, vomiting, headache, migraine, breakthrough bleeding or 
spotting, breast discomfort, weight gain, acne, increase body hair, chloasma, 
mood swings and abdominal distension.  
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2.2 The physiology of female reproductive system: 
            The principal organs of the human female reproductive tract are the 
ovaries, the fallopian tubes, the uterus, and the vagina.  Reproduction begins 
with the development of ova in the ovaries, a single ovum is expelled from an 
ovarian follicle into the abdominal cavity in the middle of each monthly sexual 
cycle, this ovum then passes through one of the fallopian tubes into the uterus, 
and if it has been fertilized by a sperm, it implants in the uterus where it 
develops into a fetus, a placenta and fetal membranes. 
             The ovarian hormones plays an important role in pregnancy, the 
different ovarian hormones are estrogen, and progesterone.  Estrogen mainly 
secreted by the growing follicles and progesterone mainly secreted by the 
corpus lutea. 
   When pregnancy occurs the ordinary ovarian cycle is suspended and the 
hormone relaxin secreted by corpus lutea and placenta ensures uterine 
quiescence and prevents early abortion of the pregnancy. 
2.3 Female Hormonal system: 
 A hypothalamic-releasing hormone, luteinizing hormone releasing 
hormone (LHRH). 
 The anterior pituitary hormones, follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH), both of which are secreted in response to the 
releasing hormone from the hypothalamus. 
 The ovarian hormones, estrogen and progesterone, which are secreted by 
the ovaries in response to the two hormones from the anterior pituitary 
gland. 
                  The various hormones are not secreted in constant amounts 
throughout the female monthly sexual cycle, but instead are secreted at 
drastically different rates during different parts of the cycle.26 
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2.4 Estrogens: 
              Estrogens are a class of steroid hormones linked principally with the 
control of female sex organ responsiveness and of reproduction.  The important 
endogenous estrogens are 7 ß-estradiol, estrone and estriol.  The most potent 
biogenic form is 17 ß estradiol.  Estrogens are biosynthesized in the ovary. 
              Estrogenic compounds derived from plants are termed 
phytoestrogens. Themajor chemical groups of phyto-estrogens are classified as 
flavonoids, (flavones, flavanones and isoflavanoids) coumastrans, lignans and 
myoestrogens. 
             These compounds interacting with the estrogenic receptor exert 
estrogenic activity, such as uterotropic effect, sterility or disruption of normal 
reproductive processes occurs in farm animals grazing in postures with plant 
sources high in phyto estrogens.  In humans cancer protective properties have 
been associated with phyto- estrogens.27 
2.4.1 Physiology of estrogens: 
Estrogens are required for the normal maturation of the female.  They 
stimulate the development of vagina, uterus and uterine tube as well as the 
secondary sexual characteristics.  They stimulate development of stroma and 
ductal growth in the breast.  They contribute to the growth of the axillary and 
pubic hair and later the distribution of body fat.  Estrogens also play an 
important role in the development of endometrial lining. An estrogen stimulates 
the synthesis of enzymes and growth factors leading to uterine growth and 
differentiation.  In the liver estrogens alter the circulating levels of proteins such 
as transcorin (CBG) thyroxine-binding globin (TBG) sex hormone-binding 
globin (SHBG), tranferrin, renin substrate and fibrinogen.  This leads to 
increased circulating levels of thyroxine, estrogen testosterone, iron, copper and 
other substances.  Estrogens enhance the coagulability of blood.  Alteration in 
the composition of the plasma lipids caused by estrogens is characterized by an 
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increase in the high-density lipoproteins and a reduction in plasma cholesterol 
level.  Plasma triglycerides levels are increased.28 
 
2.4.2 Mechanism of action of estrogen: 
                Estrogen may act on the hypothalamic center to inhibit the secretion 
of gonadotropin releasing factor thereby preventing pituitary gonadotropin 
secretion and the resultant ovulation.  The transport of ova through the tubules 
is either accelerated or inhibited so that the ova enter the unprepared uterus 
where it is degenerated or expelled.  Administered estrogens also alter the 
delicate balance of estrogen and progesterone required for implantation of the 
blastocyte in the endometrium. 
     Estrogens also induce the formation of hormonal receptors necessary for 
the interaction of the different hormones.  Most of the actions of estrogens are 
mediated by the activation of intracellular receptors.29 
     Estrogens exert their action by inducing specific physiologic response till 
the estrogenic receptors.  The estrogenic receptors reside in the nucleus and the 
hydrophobic estrogenic compounds readily diffuse through the cellular and 
nuclear membrane to bind and subsequently activate the estrogenic receptors.  
The activated form of the estrogenic receptors can then stimulate the 
transcription of estrogen responsive genes. 
2.4.3 The important biological activities of estrogen: 30 
a) Stimulation of growth of both the myometrium and endometrium. 
b) Maintenance of a thick vaginal mucosa and indirectly the acidic vaginal 
pH. 
c) Stimulation of cervical glands to secrete copious quantities of viscous 
mucous. 
d) Stimulation of breast growth and development. 
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e) Deposition of subcutaneous fat which results in a characteristic feminine 
habitus. 
f) Regulation of gonadotropin secretion including both “negative” and 
“positive” Feedback. 
g) Sensitization of the ovaries to gonadotrapins and 
h) Retardation of linear body growth in association with facilitation and 
epiphyseal closure. 
2.5 Ovarian cycle: 26 
              The normal reproductive years of the female are characterized by 
monthly rhythmic changes in the rates of secretion of the female hormones and 
corresponding changes in the ovaries and sexual organs as well.  This rhythmic 
pattern is called the female sexual cycle (or less accurately, the menstrual 
cycle).  The duration of the cycle averages 28 days.  It may be as short as 20 
days or as long as 45 days even in completely normal women, though abnormal 
cycle length is occasionally associated with decreased fertility. 
             The two significant results of the female sexual cycle are: First, only a 
single mature ovum is normally released from the ovaries each month.  Second, 
the uterine endometrium is prepared for implantation of the fertilized ovum at 
the required time of the month. 
            After puberty, when FSH and LH from the anterior pituitary gland begin 
to be secreted in large quantity, the entire ovaries together with the follicle 
within them begin to grow. 
            Disturbance of the natural steroid hormone balance can successfully 
disorganize the co-ordinated events involved in ovulation, ovum transport and 
implantation. Thus, compounds possessing oestrogenic, progestation, anti-
oestrogenic or anti progestational activity may also exhibit anti-fertility 
activity.31 
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2.5.1 Ovulation: 32, 33 
                About 14th day of normal - 28 day menstrual cycle a mature graffian 
follicle ruptures to expel ovum.  The egg and its associated cells enter the 
peritoneal activity briefly, and then pass in to fimbriated funnel of the oviduct.  
The fimbriae of the duct are close to the surface of the ovary at this time.  The 
ovum must be fertilized soon after ovulation or it will degenerate, fragment and 
disappear.  The union of the ovum and sperm takes place either before or 
immediately after the ovum enters the fimbriated extremity of the tube. The 
ovum reaches the uterus about 3 days after ovulation. Then embryo implanted in 
the endometrium about 6 days after ovulation. Prostaglandin's released by 
endometrial cells facilitate this process. 
                After ovulation, the ruptured follicle does not degenerate at once but 
is transformed temporarily into a glandular structure, the yellow body or corpus 
lutea. 
2.5.2 Initiation of Ovulation: 26 
            The initiating cause of ovulation is the large quantity of luteinizing 
hormone secreted by the anterior pituitary gland.  The luteinizing hromone in 
turn causes rapid secretion of follicular steroid hormones containing a small 
amount of progesterone for the first time.  Within a few hours two events 
occurs, both of which are necessary for ovulation. 
            1)   The theca externa (the capsule of the follicle) begins to form 
proteolytic enzymes that cause dissolution of the capsular wall and consequent 
weakening of the wall, resulting in further swelling of the entire follicle and 
degeneration at the stigma. 
2)  Simultaneously, there is rapid growth of new blood vessels into the 
follicle wall, and at the same time prostaglandin's (local hormones that 
cuase vasodilation) are secreted in the follicular tissues. These two 
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effects in turn cause plasma tansudation into the follicle, which also 
contributes to follicle swelling.  Finally, the combined follicle swelling 
and simultaneous degeneration of the stigma cause follicle rupture with 
evagination of the ovum. 
2.6 The corpus luteum – The “Lueteal” phase of the ovarian cycle: 
                   During the first few hours after expulsion of the ovum from the 
follicle, the remaining granulosa cells change rapidly into lutein cells. These 
grow to a diameter two or more times as large as the granulosa cells, and they 
become filled with lipid inclusions that give them a yellowish appearance.  This 
process is called luteinization, and the total mass of cells together is called the 
corpus luteum.  In the normal female, the corpus leuteum grow to 
approximately 1.5 cm.  
The two types of ovarian sex hormones are the estrogens and the 
progestins, the most important of the estrogens is the hormone estradiol, and by 
far the most important progestin in progesterone.  The estrogens mainly 
promote proliferation and growth of specific cells in the body and are 
responsible for development of most secondary sexual characteristics of the 
female.  On the other hand, the progestins are concerned almost entirely with 
final preparation of the uterus for pregnancy and the breasts for lactation.23 
2.7 Role of sperms in fertilization: 
                   Semen is the complete discharge of the male during normal 
ejaculation. It consists of seminal plasma, spermatozoa and usually some cells 
cast off from the lining of the reproductive ducts and glands.  Seminal plasma 
consists of the secretion of the prostate, seminal vesicles, bulbourethral glands 
and epididymis, the chief contribution being from the prostate and seminal 
vesicles.  The seminal plasma serves as a food source and vehicle for the 
spermatozoa. 
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                Testicular or epididymal sperm are inactive but quickly become active 
in seminal plasma (or saline).  The role of the high content of hyaluronidase in 
sperm is not entirely understood but histochemical studies indicate that it breaks 
down the egg coating and aids the sperm in penetrating the egg.34 
              The production of spermatozoa occurs in the seminiferous tubules of 
the testis which are controlled by hormones from anterior pituitary gland.  
Leutinizing hormones (LH) stimulate the interstitial cells of leydig to produce 
testosterone. Testosterone is responsible for appearance of maintenance of 
secondary sex characteristics.  The male accessory sex organs are the organs 
adopted for transfer of live spermatozoa from males to female. Sperm must 
remain in female tract for several hours to acquire ability to penetrate ovum-
capacitation.35 
               As early as the 19th Century B.C. the Egyptians were mixing honey, 
natron (Sodium carbonate) and crocodile dung to form a vaginal contraceptive 
paste.  During the middle ages, rock salt and alum were frequently used as 
vaginal contraceptives. The spermicidals must be inserted deep in to the vagina 
(usually with an applicator). They must be used just before intercourse and 
reused if intercourse is to be repeated. The ideal vaginal contraceptive must be 
non toxic and non irritating to both partners. The spermicidal agents also 
provide significant protection against venerial disease transmission.  Modern 
spermicidal reagents or vaginal contraceptives fall in to 3 Categories.36 
1.  Surface active / sulfydryl binding agents 
    Eg.  (i)  Non oxynol – I.U.S.P. (Delfen, Immolin) 
           (ii)  Otoxynol U.S.P. (Koromex) 
2.  Bactericides 
    Eg.  (i)  Phenyl mercuric acetate (Lorophyn) 
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           (ii)  Benzenthonium chloride 
           (iii)  Methyl enethonium chloride 
           (iv) Phenyl mercuric borate 
3.  Acids 
    Eg.   Boric acid, Tartaric acid, Phenols etc 
            Contraception is literally the prevention of conception, but generally is 
taken to mean the prevention of pregnancy.37 
2.8 Mechanism of steroid hormone action: 
                Estradiol, like other steroids, is thought to exert its action directly on 
the nucleus of the cell.  As a consequence, an estrogen-response tissue must 
have estrogen receptor and nuclear acceptor sites to which activated receptor 
can bind. Upon entry into the cytosal of the cell (by diffusion), estradiol is 
bound to a specific receptor (ERc).  In the cytoplasm, the estrogen receptor 
complex is activated (ERn) and translocated to the nucleus.  This complex binds 
to acceptor sites in chromatin and enhances processes associated with 
differentiated functions of the responsive tissue, which include the production 
and utilization of messenger and other classes of RNA needed for the synthesis 
of constituent enzymic and secretory proteins, as well as the receptor itself. In 
some cells replication of DNA is also stimulated, followed by cell division.  The 
concentration of estrogen receptors in most tissues is constitutive but in some 
instances it is increased by estradiol. 
            The concentration of progesterone receptors in the uterus and other 
progesterone response tissues is markedly increased by estrogen.  In fact, one of 
the recognized actions of estradiol is to stimulate synthesis of progesterone 
receptors. The induction of progesterone receptors with estrogen can explain the 
synergistic action of these two hormones on the uterus. 
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2.9 Arachidonic acid pathway: 
Arachidonic acid (AA) is an essential fatty acid consumed in the diet or 
derived from elongation and desaturation of dietary linoleic acid (LA).38 AA 
metabolism is linked to signal transduction pathways that result in the 
activation of phospholipase C (PLC) and phospholipase A2 (PLA2).39, 40, 41, 42 
once AA is released from phospholipids it is oxidized by one of three different 
oxygenases.38, 43 A certain cytochrome P-450 inserts a single oxygen atom into 
the double bond of AA to produce epoxy-arachidonic acids.43 Lipoxygenases 
introduce one molecule of 02 into the carbon framework of AA to produce a 
series of isomeric hydroperoxy acids.44 These hydroperoxy fatty acids are 
converted to hydroxy fatty acids, to leukotrienes (LTs) and to lipoxins.38, 43, 44 
Cyclooxygenase introduces two molecules of 02 into AA to form the 
hydroperoxy endoperoxide prostaglandin (PG) G2, which is reduced by the 
peroxidase activity to the hydroxy endoperoxide, PGH2.38, 45, 46, 47 PGH2 is 
transformed to PGs, thromboxanes (TXs), prostacyclin, and 
malondialdehyde.38 The physiological response to AA oxygenation in a given 
tissue is largely determined by the levels of PGH2-metabolizing enzymes in the 
cells making up that tissue. Each PG has its own range of biological activities. 
The LTs constitute a family of highly potent inflammatory mediators which are 
derived from the 5- lipoxygenase pathway of AA metabolism.48, 49, 50 
Eicosanoids are not stored but are synthesized on demand; therefore inhibitors 
of the various oxygenases and peroxidemetabolizing enzymes have 
instantaneous effects on eicosanoid levels.51, 52 
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Figure 3: COX and LOX pathways of AA metabolism. Metabolites of COX 
pathway are called prostaglandins G2 (PGG2), E2 (PGE2), H2 (PGH2), D2 
(PGD2), F2α (PGF2α), thromboxane A2 (TXA2), malondialdehyde (MDA), and 
prostacyclin (PGl2). Metabolites of the LOX pathway are called 12- and 5-
hydroperoxyeicosatetraenoic acids (HPETEs), and their corresponding fatty 
acids (HETEs). Leukotriene A synthase (LTA synthase) generates the 
leukotrienes. 
 
2.10 Biosynthesis of leukotrienes: 
Unlike many other biologically active molecules, the eicosanoids are not 
stored preformed but are synthesized de novo from membrane phospholipids 
(arachidonic acid) through a cascade of enzymes. Arachidonic acid (5,8,11,14-
cis-eicosatetraenoic acid) is found esterified in the sn-2 position, to cell 
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membrane phospholi- pids in a wide variety of mammalian cells.53 The trigger 
for eicosanoid biosynthesis begins after trauma, infection and inflammation.54 
The initial step in the biosyn- thesis is a receptor-mediated influx of calcium 
ions that causes translocation of a phospholipase enzyme, cytosolic 
phospholipase A sub 2 (phospholipase A2), to the cell membrane.55, 56, 57 The 
enzyme then catalyses the hydrolysis of the esterified form of arachidonic acid 
at its sn-2 position.58 This selectively cleaves arachidonic acid from cell 
membranes. 
  There are three major pathways of metabolism from arachidonic acid 
as the substrate – the cyclo-oxygenase, lipoxygenase and epox- ygenase 
pathways.59 The cyclo-oxygenase pathway leads to the formation of 
prostaglandins and thromboxanes while the lipoxygenase pathway is 
responsible for initiating the synthesis of leukotrienes. The third pathway (the 
epoxygenase pathway) is probably least important and also poorly understood; 
although it leads to the formation of prostaglandin epoxides which are thought 
to play a role in bleeding disorders. Only the second pathway (the lipoxygenase 
pathway) will be discussed in detail here. 
        The activity of phospholipase A2 is increased by a phospholipase A2-
activating protein. This protein, when activated by cytokines e.g. tumour 
necrosis factor (TNF) and interleukin-1 (IL-1), can lead to arachidonic acid 
release and subsequent leukotriene formation. Arachidonic acid is then 
converted sequen- tially to 5-hydroperoxyeicosatetraenoic acid (5 HPETE) and 
then to LTA4 by a catalytic complex consisting of 5-LO and FLAP in the 
presence of adenosine triphosphate (ATP) and calcium ions (Ca2+).60, 61 LTA4 
is unstable and is either metabolized by LTA4 hydrolase to leukotriene B 
(LTB) sub 4 or conjugated to the tripeptide glutathione (γ-
glutamylcysteinylglycine) by LTC4 synthase (a unique glutathione S-
transferase) to form LTC4. In many biological systems, LTC4 is then rapidly 
converted to LTD4 via γ-glutamyl transpeptidase, which removes the amino 
acid glutamic acid from the glutathione moiety. LTD4 may then be converted 
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to LTE4 by the actions of a dipeptidase, which removes the glycine residue. 
This leaves cysteine as the only amino acid conjugated to the lipid portion of 
LTE4. Because LTC4, LTD4 and LTE4 contain cysteine, they have been 
designated cysteinyl leukotrienes. LTB4 can undergo further oxidation at the 
20-carbon atom to the less active metabolites. 
 
 
2.11 Distribution of leukotrienes: 
               The term leukotriene is derived from leukocytes because they were 
initially identified as products of leukocytes and the chemical structure contains 
three conjugated double bonds (triene). Apart from leukocytes, other myeloid 
derived cells can produce leukotrienes. The sites at which the leukotrienes are 
synthesized are determined by the cellular distribution of the enzymes 
controlling each stage of the biosynthetic pathway. The synthesis of LTA4 is 
limited to cells of the myeloid lineage, which are the primary sites of 5-LO. 
However, the enzymes determining the next step in the biosynthetic pathway 
(conversion to either LTB4 or the cysteinyl leukotrienes) are more widely 
distributed. This enables a much broader range of cells to act as leukotriene 
producers. 
 The distribution of 5-LO is limited to neutrophils, eosinophils, 
monocytes, macrophages, mast cells, basophils and B-lymphocytes.62, 63 
Considerable variation exists in both the type and the quantity of leukotrienes 
secreted in these cells. Apart from human monocytes and macrophages which 
produce both LTB4 and LTC4 all the other cells produce appreciable quantities 
of either LTB4 or LTC4 but not both. LTC4 is the principal 5-LO product 
released from activated eosinophils64, 65, 66 as well as purified pulmonary mast 
cells while activated neutrophils secrete LTB4 as a product of 5- LO activity.67 
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            The main sites of leukotriene production in the body by the myeloid 
derived cells that have been demonstrated are the lungs68, 69, 70, 71 and the 
uterus.72, 73, 74, 75, 76 The other potential sites of production are the kidneys77 the 
skin of patients with urticaria, atopic dermatitis and psoriasis78 the coronary 
circulation in patients with cardiac ischaemia and in the biliary system 
following human bile duct obstruction.79 Increased concentrations of LTB4 and 
the cysteinyl leukotrienes are found in the sputum, bronchoalveolar lavage 
fluid, and urine of patients with cystic fibrosis. 80, 81, 82, 83 Some other conditions 
in which leukotriene production is increased are inflammatory bowel disease,84 
sickle cell disease and rheumatoid arthritis.85 In the gut, LTB4 is found in 
colonic epithelial cells where synthesis is thought to take place and it is 
believed to promote infiltration by neutrophils of injured colonic mucosa in 
patients with inflammatory bowel disease. In patients with ulcerative colitis 
and Crohn’s disease, the colonic mucosa contains significantly elevated 
concentrations of LTB4 compared with normal controls.86, 87 LTB4 
concentrations are also substantially elevated in the rectal dialysate fluid of this 
group of patients. 88, 89 
2.12 Leukotriene receptors:  
               Leukotrienes produce their biological effects by binding to and acti- 
vating specific receptors. Two types of receptors for the cysteinyl leukotrienes 
(CysLT1 and CysLT2) have been demonstrated.90 Recently, the molecular and 
pharmacological characteristics of cloned human CysLT1 receptor have been 
reported.91 The CysLT1 receptor (designated HG55) is a glycosylated G-
protein-coupled receptor (GPCR) 92 and it encodes a protein of 337 amino acids 
with a molecular mass of 38 549. All the three marketed cysteinyl leukotriene 
antagonists were demonstrated to be potent competitors with the CysLT1 
receptor for binding of radiolabelled LTD4. Such characterization has so far 
not been elucidated for CysLT2 receptor. The receptor for the non-cysteinyl 
leukotriene (LTB4), is a seven-transmembrane- spanning protein known as the 
B leukotriene receptors (BLT).93 These G-coupled receptors are members of 
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the rhodopsin-like receptor superfamily.94 
 The leukotriene receptors are located in the plasma membranes of 
smooth muscle cells and in other types of cells. 95, 96, 97  Most of the biological 
effects of the leukotrienes are mediated by the CysLT1 receptor.98 These 
effects include the contrac- tion of human airway smooth muscle, chemotaxis, 
and increased vascular permeability.99 LTC4 and LTD4 have equal capacity to 
stimulate smooth muscle contraction in the human lung in vitro by acting on 
CysLT1 receptors and the potency of LTE4 is lower by a factor of 10.100 In the 
uterus, cysteinyl leukotrienes have also been demonstrated to stimulate 
myometrial smooth muscles (both circular and elongated myometrial smooth 
muscle) where specific binding sites have been demonstrated. Similar binding 
sites have also been demonstrated in the endometrial cells. The action of the 
CysLT2 receptor is less well defined although in humans, they have been 
shown to mediate contraction of pulmonary vascular smooth muscle. 
Two distinct sites of high and low affinity for LTB4 exist on the surface 
of neutrophils. LTB4 is a very potent neutrophil chemotactic agent and may 
play a pivotal role in the induction of neutrophil–endothelial cell adherence as 
well as a mediator of inflammatory pain.  
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             Figure 4: Biochemical Pathways of the Formation and Action of the  
             Leukotrienes and Sites of Action of Leukotriene-Modifying Drugs. 
 
 
2.13 Leukotrienes in the uterus: 
           The ability of uterine tissues to elaborate leukotrienes was first 
suggested in the guinea pig using the leukotriene receptor antago-nist FPL 
55712, which inhibited antigen-induced uterine contrac- tions.101 Although 
several other studies were conducted after this initial experiment to 
demonstrate increased amounts of leukotrienes in the endometrium and 
myometrial smooth muscles of patients with primary dysmenorrhoea little has 
been done on the potential therapeutic role of anti- leukotrienes in the 
management of this condition. 
Leukotriene receptors were shown to be present in uterine tissues in the 
1980s.102 The number of these receptor sites for the cysteinyl leukotrienes has 
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been demonstrated to be as high as that in lung. Incubation studies using light 
microscopic autoradiographs of non-pregnant human uterine and bovine lung 
tissues demonstrated the presence of specific LTC4 receptor sites in 
endometrial and myometrial smooth muscle cells. Experimental studies carried 
out by Demers et al. (1984) using human endometrium and myometrium 
demonstrated the capacity of these tissues to synthesize leukot- rienes. In the 
menstrual blood from women with primary dysmenor-rhoea compared with 
that in women without, significantly higher concentrations of LTC4 and LTD4 
have been demonstrated. The presence of specific LTC4 binding sites in the 
myometrial cells have also been localized.103 
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2.14 DRUG PROFILE  
 
MONTELUKAST SODIUM 
Category : Antiasthmatic104 
     Structure             
                                             
                                                              Montelukast sodium 
 
Chemical Name: 2-[1-[[1-[3-[2-[(7-Chloro-2-quinolyl)] vinyl] phenyl]-3-[2-
(1-hydroxy-1-     methyl-ethyl)phenyl]-
propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;105 
Molecular formula: C35H35ClNNaO3S 
Molecular Weight: 608.17 g/mol 
Physical appearance: white to off-white powder. 
Solubility: Montelukast sodium is freely soluble in ethanol, methonol and 
water and practically insoluble in acetonitrile.106 
Description: Montelukast sodium is a selective and orally active leukotriene 
receptor antagonists that inhibits the cysteinyl leukotriene CysLT1 receptor.107 
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Mechanism of action: The Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) 
are products of arachidonic acid metabolism and are released from various 
cells, including mast cells and eosinophils. 
             These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) 
found in the human airway. Cysteinyl leukotrienes and leukotriene receptor 
occupation have been correlated with the pathophysiology of asthma, including 
airway edema, smooth muscle contraction and altered cellular activity 
associated with the inflammatory process, which contribute to the signs and 
symptoms of asthma. It reduces the sputum eosinophil levels and causes 
bronchodilation. 
              Montelukast is as orally active compound that binds with high affinity 
and selectivity to the CysLT1 receptor (in preference to other 
pharmacologically important airway receptors such as the prostanoid, 
cholinergic or adrenergic receptor). Montelukast inhibits physiologic actions of 
LTD4 at the CystLT1 receptor without any agonist activity. It reduces the 
bronchial hyperesponsiveness, improves the lung function, and reduces 
bronchial inflammation.108 
Available & recommended dosing: 
Dose-finding studies indicate an optimum therapeutic dose of 10 mg/day 
in adults and adolescents.109,110 Determination of the optimum daily dose of 5 
mg in children aged 6–14 years111 and 4 mg in infants as young as 6 months of 
age112 is based on serum blood levels of the drug.. The 4 mg tablet formulation, 
unlike the others, should be administered either 1 h before or 2 h after food, as 
it may be better absorbed in an empty stomach.113 The dosage for all 
formulations is one tablet/dose daily at bedtime. 
Pharmacokinetics: Bioavailability (%)                  -    63 
                                  Protein Binding (%)                -   greater than 99 
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                                  Elimination half life (hrs)        -   2.7 to 5.5 
                                  Routes of administration          - oral 
Absorption:  Montelukast sodium is well absorbed upon oral administration. 
Peak blood levels occur in about 2-2.5 hrs, with a half-life of 2.7-5.5 hrs. 
Distribution: Montelukast sodium protein binding is greater than 99 % 
Metabolism: Extensively metabolized. Plasma concentrations of metabolites 
are undetectable at steady state. CYP-450 3A4 and 2C9 are involved in 
metabolism. 
Excretion: Montelukast sodium is eliminated by urine. Plasma clearance 
averages 45 ml/min. 86% recovered in feces and less than 0.2% in urine. 
Pharmacodynamics: Montelukast causes inhibition of airway cysteinyl 
leukotriene receptors as demonstrated by the ability to inhibit 
bronchoconstriction due to inhaled LTD4 in asthmatics. Doses as low as 5 mg 
causes substantial blockage of LTD 4- induced bronchoconstriction. In clinical 
studies it decreased mean peripheral blood eosinophils approximately 13-15% 
from baseline compared with placebo over the double behind treatment 
periods.114 
Drug Interactions: Phenobarbital, rifampicine. 
Side Effects: These are in general few consisting headache and gastrointestinal 
disturbances. Few subjects developed Churg-Strauss syndrome (it’s 
characterized by systemic vasculitis eosinophilia and a history of asthma, 
sinusitis and rhinitis). Cardiovascular - Cardiac complications, palpitations 
(post marketing).115 
Usage: Montelukast sodium is used in prophylaxis and chronic treatment of 
asthma in patients 12 months of age and older; relief of symptoms of seasonal 
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allergic rhinitis in patients 2 yrs of age and older; relief of symptoms of 
perennial allergic rhinitis in patients 6 months of age and older.116 
Diet: Reduces bioavailability. 
Storage: Store at controlled room temperature (59° to 86°F). Protect from 
moisture and light.117 
The estrous cycle in female rats is of 4–5 days duration and divided into 
four phases: proestrus (12–18 h) estrus (25–38 h), metestrus (5–8 h) and 
diestrus (47–58 h).118 
2.15 Various stages of the estrus cycle in rats: 
The estrus cycle is a cascade of hormonal and behavioural events, which 
are highly synchronised and repetitive. The short and precise estrus cycle of 
laboratory rat has been a useful model for reproductive studies.  The laboratory 
rat is a spontaneous ovulating, non-seasonal, polyestrus animal. It ovulates 
every 4-5 days throught the year unless interrupted by pregnancy or pseudo-
pregnancy. 
Rats estrus cycles is roughly divided into four stages. 
2.15.1 Proestrus: This is the beginning of a new cycle. The follicles of the 
ovary start to mature under the influence of gonadotropic hormones, and 
estrogen secretion start increasing. The vaginal smear is characterised by 
nucleated epithelial cells, the stage lasts for about 12 h. 
2.15.2 Estrus: In this stage the uterus is enlarged and extended and extended 
due to fluid accumulation; estrogen secretion is at its peak. In the estrus stage, 
the smear shows presence of squamous cornified cells (hexagonal or 
pentagonal cells). The estrus stage is usually the period of heat and is 
characterised as a period of sexual receptivity, when the female allows 
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copulation. During this stage there is increased running activity. It lasts for 12 
h. 
2.15.3 Metestrus: The ovary contains corpora lutea which secrete 
profesterone. This stage is indicated by the presence of a mixture of cornified 
epithelial cells and leucocytes indicating the post-ovulatory stage and 
desquamation of the epithelial cells. The metestrus stage lasts for about 21 h. 
2.15.4 Diestrus: the corpus lutea regress and the declining secretion of 
estrogen and progestrone cause regression of the uterus. The vaginal smear 
shows onlu leucocytes. This stage is the longest phase of the estrus cycle and 
has duration of about 57 h. 
2.16 The experimental procedure for taking vaginal smears:  
Holding the animal on the ventral side up, a drop of normal saline is 
inserted into the vagina with a pasteur pipette. Care must be taken to avoid 
damage or injury to the vagina so as to pseudo-pregnancy. The drop of normal 
saline should be aspirated and replaced several times. It is then transferred to a 
microscope slide and allow to dry. The smear are fixed by placing the slide in 
absolute alcohol for  5 s, allowing it to dry, and  staining it with a 5% aqueous 
methylene blue solution for 10min. the excess stain is washed off with tap 
water, and the slide dried  and observed using a low power microscope.1 
2.17 Role of leukotriene in reproduction:  
The lipoxygenase products (leukotrienes) have been demonstrated in 
many mammalian tissues including humans. They are widely distributed in the 
lungs, gut, uterus, kidneys, skin, heart and the liver. Their roles as mediators of 
inflammation have made them therapeutic targets. The potential use of 
lipoxygenase products in the management of primary dysmenorrhoea 
(especially in patients who are not responding to the traditional treatment using 
PG synthetase inhibitors) and possibly also in cases of endometriosis.10 
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Leukotrienes modulate steroidogenic cells functions, depending on the 
stage of the cycle. Leukotriene B (4) plays a luteotropic role stimulating P4 and 
PGE (2) secretions; LTC (4) stimulates the secretion of luteolytic factors and 
enhances the luteolytic cascade within BCL.119 
2.18 Role of leukotriene in ovulation: 
The concentrations of PGE, PGF, LTB, and LTC4/D/E increase in the 
ovary of PMSG-primed immature rats after the ovulatory process has been 
initiated by hCG administration. Since differences in the patterns of temporal 
changes of the various eicosanoids during ovulation are seen, we suggest that 
each eicosanoid plays a distinct role in the process of follicular rupture.11 
Pharmacological inhibition of an alternative lipoxygenase (LOX) 
pathway has been shown to cause defective ovulation. The expression of 
ALOX5 and ALOX12 in the preovulatory follicle and that inhibiting the early 
phase LOX activity led to reduction in preovulatory PTGS2 induction and 
PGE2 production and thus defective ovulation. These findings may help to 
understand the mechanism for the involvement of the LOX pathway in LH-
triggered ovulatory response, at least the induction of PTGS2 activity, in rats.12 
LTB4 may play a role in the ovulatory pathways of the rat ovary and 
that LTB4 may carry out its effects via MMP-2.13 
Rats treated with the LOX inhibitor NDGA (300 mg/kg bw) did not 
show ovulatory alterations. These data indicate that the characteristic 
alterations of follicle rupture induced by indomethacin, are also induced by 
selective COX-2 inhibitors, strengthening the contention that prostaglandins 
play a crucial role in the spatial targeting of follicle rupture at the apex.120 
NDGA appears to be an inhibitor of ovulation in the rat. LTB 4 reversed 
the ovulation inhibition by NDGA, suggesting a role of this LT in intraovarian 
ovulatory changes. Steroidogenesis was marginally affected only when both the 
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lipoxygenase and cyclooxygenase pathways were inhibited and was associated 
with reduced PG levels. However, these findings must be couched in the 
understanding that neither the lipoxygenase nor the cyclooxygenase pathway is 
indispensable for ovulation to take place. This study further highlights the 
activities, interactions, overlap, and redundancy of arachidonic acid pathways 
supporting ovulation.14 
2.19 Role of leukotriene in pregnancy: 
Lipoxygenase metabolites may be involved in human parturition. Role 
for 5-LOX and FLAP in the control of parturition at term, and also suggest an 
involvement earlier in pregnancy.19 
HSD11B2 in human placental trophoblasts is decreased by progesterone 
and increased by inhibition of endogenous LOX metabolites, and that a 
component of the effect of LOX metabolites on HSD11B2 is mediated by their 
stimulation of endogenous progesterone output.20 
Lipoxygenase from human term placenta exhibits both dioxygenase and 
hydroperoxidase activities, and this enzyme represents an important pathway 
for chemical oxidation in the placentas of non-smoking women.121 
LT action in the bovine reproductive tract is dependent on LT type: 
LTB(4) is luteotropic during the estrous cycle and supports early pregnancy, 
whereas LTC(4) is luteolytic, regarded as undesirable in early pregnancy. LTs 
are produced/secreted in the CL tissue, influence prostaglandin function, and 
serve as important factors during the estrous cycle and early pregnancy in 
cattle.122 
  Paracrine loop between LTB4 and oxytocin is lacking in fetal 
membranes and amnion at term pregnancy. Oxytocin exerts a stimulatory effect 
on PGE2 release by both fetal membranes and amnion. The interrelationships 
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between oxytocin and the different eicosanoids in the above tissues seem to be 
highly selective.123 
The affinity of PGF2 alpha to the uterus and the role of endogenous PGs 
in the maintenance of pregnancy by influencing connective tissue 
metabolism.124 
 The arachidonate lipoxygenase pathway is highly active before labor; 2) 
LTB4 might play a role in the regulation of PGE2 production.125 
Activation of protein kinase C can result in enhanced production of 
arachidonate lipoxygenase metabolites that may have actions on the parturient 
process.126 
LTB4 may play an important role in both placental separation and 
uterine involution in cattle and LTB4 synthesis may be modulated by endocrine 
and bacterial factors.127 
Nordihydroguaiaretic acid, a leukotriene inhibitor, reduced PGE release 
as well as 6-keto-PGF1 alpha.128 
A critical role for LTB4 in averting NK-mediated early spontaneous 
fetal resorption.129 
A large variation of 12-HETE production it remains to clarify its role in 
the cervix.130 
An activation of the arachidonate lipoxygenase pathway in these tissues 
during labor. Oxytocin could play a regulatory role in this process.131 
The potentiation of contraction force to oxytocin by CRH is dependent 
on prostaglandins, probably PGF2 alpha and that leukotrienes, generated via 
the lipoxygenase pathway are not involved.132 
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5-HETE and LTC4, but not PGF2 alpha, are associated with uterine 
contractility after preterm intrauterine surgery. Surprisingly, AF PGF2 alpha 
levels were nondetectable for 1 to 2 weeks after surgery. 5-HETE and LTC4 
are present in higher concentrations than PGF2 alpha in AF. 5-HETE, LTC4 
and PGF2 alpha all increase with the onset of labor. AF concentrations of 5-
HETE and LTC4 are significantly higher than PGF2 alpha before and during 
term and preterm labor. Labor can occur with suppressed PGF2 alpha levels, 
but with increasing 5-HETE and LTC4 levels. These data suggest that 5-HETE 
and LTC4 are important components of the parturitional process, and they 
challenge the dogma that PGs are the universal mediators of labor.133 
5-HETE and LTC4, but not PGF2 alpha, are associated with uterine 
contractility after preterm intrauterine surgery. Surprisingly, amniotic fluid 
PGF2 alpha, levels were nondetectable for 1 to 2 weeks after surgery. 5-HETE 
and LTC4 are present in higher concentrations than PGF2 alpha in amniotic 
fluid. 5-HETE, LTC4, and PGF2 alpha all increase with the onset of labor. 
Amniotic fluid concentrations of 5-HETE and LTC4 are significantly higher 
than those of PGF2 alpha before and during term and preterm labor. Labor can 
occur with suppressed PGF2 alpha levels but with increasing 5-HETE and 
LTC4 levels. These data suggest that 5-HETE and LTC4 are important 
components of the parturitional process.134 
Both PGs and LTs are required for the induction and progression of 
decidualization.21 
There is an interaction between LTs and PGs in the induction of the 
uterine decidual response.135 
Metabolism of arachidonic acid (AA) via cyclooxygenase to 
prostaglandins and thromboxanes and via lipoxygenase to 
hydroxyeicosatetraenoic acids (HETEs) and leukotrienes is an integral part of 
both the acute and chronic inflammatory reaction in the lung or uterus.136 
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2.20 Role of leukotriene in fertilization 
Mouse and human spermatozoa require cysteinyl leukotriene activity for 
both fertilization and oocyte penetration.18 
2.21 Role of leukotriene in implantation 
LTs in uterine functions during implantation processes and 
decidualization has been reported.15, 16 A selective inhibitor of 5-lipoxygenase 
enzyme may not impair the implantation in mice indicating a doubt about the 
involvement of 5-lipoxygenase products in implantation.137 
The presence of both the cyclooxygenase and the lipoxygenase 
pathways in the preimplantation rabbit uterus and blastocyst, their differential 
operation in various compartments of the uterus on various days of early 
pregnancy suggests an integrated role for these mediators in embryo-uterine 
interaction during implantation.17 
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CHAPTER-3 
OBJECTIVES 
The objective of the study was to evaluate the “Anti-fertility activity of 
montelukast, a cysteinyl leukotriene receptor antagonist in female albino 
Wistar rats” with the following headings. 
 To evaluate the effect of montelukast on pre-implantation  in 
albino Wistar rats 
 To evaluate the effect of montelukast on post-implantation in 
albino Wistar rats 
 To evaluate the effect of montelukast on anti-fertility activity in 
albino Wistar rats 
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CHAPTER-4 
 MATERIALS AND METHODS 
4.1 Animals 
Inbred female (100-150 g) and male (150-250 g) albino Wistar rats were 
obtained from Swamy Vivekanandha College of pharmacy, animal house and 
maintained under standard conditions at 21±1o C and 50-60% relative humidity 
with a photoperiod of 12 h light: 12 h dark. The animals were fed with standard 
pellet diet and water ad libitum. The protocols received prior approval from the 
Institutional Animal Ethical Committee (SVCP/IAEC/M.Pharm/06/2011) and 
experiments were conducted in accordance with guidelines set by the CPCSEA 
(Committee for the purpose of control and supervision of experiments on 
animals), India. 
4.2 Drugs: 
A gift sample of Montelukast obtained from (Ranbaxy Labs Ltd., 
Mumbai) was used for the study. 
 4.3 Chemicals: 
Carboxy methyl cellulose (Loba Chemie Pvt. Ltd., Mumbai). 
Betadine (G.S.Pharmbutor Pvt. Ltd., Rudrapur).  
Neosporin (Glaxo Smithkline Pharmaceutical Ltd. Bangalore). 
4.4 Instruments: 
Compound microscope (I.R.Technology Services Pvt. Ltd., Mumbai). 
Surgical catguts (Johnson & Johnson Pvt.Ltd., Mumbai). 
35 
 
Pipettes (Riviera Glass Pvt. Ltd., Mumbai). 
Silk thread (Neelam Thread Pvt. Ltd., Delhi). 
4.5 Anti-Implantation Activity 
Vaginal smears of the female were taken daily for assessment of their 
oestrus cycle. Adult female albino Wistar rats of established fertility in pro-
oestrus and oestrus were housed with mature male rats of established fertility 
(three females for one male). On mating days, females of the appropriate 
weight were placed in cages with males for approximately 14 h. Each female 
was examined for the presence of spermatozoa in the early morning vaginal 
smears. The first presence of sperms in the vaginal smear was taken as day 1 of 
pregnancy. In rats, implantation occurs on day 5 of pregnancy. 
The female rats which had mated were then separated and caged singly. 
They were divided into four different groups consisting of six animals each.  
The various groups were treated as follows: 
The drug were administered orally once daily through gastric gavage 
from 1-7 days of pregnancy and 7-21 days of pregnancy 
Group I – received the 1% w/v CMC- water suspension and served as control 
(p.o. daily). 
Group II - received Montelukast 1mg/kg body weight in 1%w/v CMC in water 
(p.o. daily). 
Group III- received Montelukast 10mg/kg body weight 1%w/v CMC in water 
(p.o. daily). 
Group IV- received Montelukast 20mg/kg body weight 1%w/v CMC in water 
(p.o. daily). 
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On day 10 of pregnancy, the animals underwent a laparotomy under light 
ether anesthesia in semisterile condition. The implants present in both uterine 
horns as well as the corpora lutea (CL) on each ovary were counted. The 
animals were allowed to complete the gestation period (21-23 days) and the 
number of litters delivered were recorded. The percentages of pre- and post- 
implantation loss and the anti- fertility activity were calculated using the 
following formula.138 
     number of CL – number of implants   
% Pre- implantation loss        =                    X  100 
            Number of  CL                                                                   
                    
 
                                                             number of implants – number of litters    
% Post- implantation loss       =                       
X  100                                                                                                                                
               number of implants 
 
 
number of CL – number of litters      
% Anti-fertility activity          =                 X   
100                                                                                                                             
                                                                 number of  CL 
                                                                                                                                                                     
4.6 Procedure for laparotomy 
The animal was lightly anesthetized with ether and limbs were tied to a 
rat board (waxed) with the ventral side up. The hairs on the area around the 
midline abdominal region were clipped with curved scissor and the region was 
cleaned with 70 % alcohol. An incision of 2 cm length was made along the 
midline to expose the viscera. The superficially lying coils of ileum were lifted 
to expose the two uterine horns. The horns were examined for implantation 
sites. Implants were visible as clear swellings on the uterine horns giving the 
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uterine tube a beaded appearance. Embryos with bright red dish aspect and a 
clear margin were considered to be healthy.  Those with dull blue color with no 
clear margin and orientation with some exudates were considered resorbing.139 
The number of implants and resorption sites per horn were counted. The 
ovaries, which lie on the upper end of the uterine horns, show corpora lutea as 
reddish yellow spots over the surface. The number of corpora lutea present on 
each ovary was also noted. 
After counting, the organs were replaced back. A small quantity of 
Neosporin powder was sprinkled over the organs to prevent any infection. The 
incision through muscular layer was closed with continuous suture using 
absorbable catguts and skin layer with continuous sutures using silk thread. An 
antiseptic, povidone iodine solution was applied on the sutured area after 
wiping with 70 % alcohol. The animal was maintained on light ether anesthesia 
throughout the experiment. After laparotomy the rats was transferred to a warm 
place till it recovered from the anesthesia.  
4.7 Statistical analysis 
The values are expressed in mean ± SEM. One way ANOVA followed by 
Tukey’s multiple comparison Test was used to analyse the effect of different 
dose of drug when compared to control, with the help of Graph Pad Instat 
software, version 3.01. P<0.05 considered as significant.    
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CHAPTER-5 
RESULTS 
5.1 The Effect of Montelukast on Implantation:-  
5.1.1Anti-implantation activity of montelukast when treated with 1-7 days 
of pregnancy 
The LOX inhibitor montelukast elicited significant pre-implantation loss 
at dose levels of 20 mg/kg (p<0.01) and the anti-fertility activity, at dose levels 
of 10 mg/kg (p<0.05), 20 mg/kg (p<0.01), when compared to control group 
(Table: 1-4, Figure: 1). 
 
 
 
 Table 1: Pre-implantation, post-implantation and anti-fertility activity of 
control group (1% w/v CMC 10 ml/kg)    
S.NO. BODY 
WEIG
HT 
NO. OF 
CORPO
RA 
LUTEA 
NO. OF 
IMPLAN
TS 
NO. OF 
LITTER
S 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTATI
ON LOSS 
% ANTI-
FERTILI
TY 
ACTIVIY 
1 180 10 7 6 30 14.28 40 
2 170 12 9 8 25 11.11 33.33 
3 190 13 8 4 38.46 50 69.23 
4 200 14 9 7 35.71 22.22 50 
5 150 12 7 5 41.66 28.57 58.33 
6 170 11 10 9 9.09 10 18.1818 
MEAN 176.6
66 
12 8.33 6.5 29.9866 22.696 44.845 
± 
SEM 
7.149 0.5774 0.494 0.7638 4.839 6.182 7.461 
± SD 17.51
2 
1.414 1.211 1.871 11.852 15.143 18.276 
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Table 2: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (1 mg/kg) 
S.NO
. 
BODY 
WEIG
HT 
NO. OF 
CORPO
RA 
LUTEA 
NO. OF 
IMPLAN
TS 
NO. OF 
LITTE
RS 
% PRE-   
IMPLANTAT
ION       LOSS 
% POST-
IMPLANTAT
ION  LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 180 15 0 0 100 0 100 
2 150 15 12 11 20 8.33 26.66 
3 200 15 0 0 100 0 100 
4 180 13 11 2 15.38 81.81 84.61 
5 160 11 8 7 27.27 12.5 36.36 
6 200 9 1 0 88.88 100 100 
MEA
N 
178.3
3 
13 5.3333 3.333 58.58833 33.773 74.605 
± 
SEM 
8.333 1.033 2.305 1.892 17.014 18.325 13.900 
± SD 20.41 2.530 5.645 4.633 41.676 44.888 34.048 
 
 
 
 
Table 3: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (10 mg/kg) 
S.NO
. 
BODY 
WEIGH
T 
NO. OF 
CORPO
RA 
LUTEA 
NO. OF 
IMPLAN
TS 
NO. OF 
LITTE
RS 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTAT
ION LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 150 11 0 0 100 0 100 
2 200 11 10 3 9.09 70 72.72 
3 170 14 11 7 21.42 36.36 50 
4 160 13 12 2 7.69 83.33 84.61 
5 170 10 2 0 80 100 100 
6 180 12 5 1 58.33 80 91.66 
MEA
N 
171.66
6 
11.833 6.666 2.1666 46.088333 61.615 83.165 
± 
SEM 
5.943 0.6009 2.060 1.078 15.977 15.042 7.853 
± SD 15.723 1.472 5.046 2.639 39.136 36.844 19.236 
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Table 4: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (20 mg/kg) 
S.NO. BODY 
WEIG
HT 
NO. OF 
CORPO
RA 
LUTEA 
NO. OF 
IMPLAN
TS 
NO. OF 
LITTER
S 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTAT
ION LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 200 9 0 0 100 0 100 
2 180 13 0 0 100 0 100 
3 190 9 0 0 100 0 100 
4 150 14 0 0 100 0 100 
5 170 13 0 0 100 0 100 
6 170 11 0 0 100 0 100 
MEA
N 
176.6
66 
11.5 0 0 100 0 100 
± 
SEM 
7.149 0.8851 0 0 0 0 0 
± SD 17.51 2.168 0 0 0 0 0 
 
 
 
Table 5: Shows anti-implantation activity of montelukast treated for 1-7 days 
of pregnancy at different dose levels of 1, 10 and 20 mg/kg body weight  
S.N
O. 
TREATME
NT 
% PRE-
IMPLANTATIO
N LOSS ( mean ± 
SEM ) 
% POST-
IMPLANTATIO
N LOSS ( mean 
± SEM ) 
% ANTI-
FERTILITY     
ACTIVIT( mean ± 
SEM ) 
 
1 Control 29.986 ± 4.839 22.696 ± 6.182 
 
44.845 ± 7.461 
2 Monteluka
st 
 (1 mg/kg) 
58.588 ± 17.014 33.773 ± 18.325 74.605 ± 13.900 
3 Monteluka
st 
(10 
mg/kg) 
46.088 ± 15.977 61.615 ± 15.042 83.165 ± 7.853* 
4 Monteluka
st 
(20 
mg/kg) 
100 ± 0.000** 00 ± 0.000 100 ± 0.000** 
 
n=6; The values are expressed as mean ± SEM; *P< 0.05, **P<0.01 when 
compared to control groups (One way ANNOVA followed by Tukey’s multiple 
comparison Test). 
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Figure 1:  Pre- and post-implantation loss (%) and anti-fertility activity (%) of 
montelukast when administered orally at various dose levels to female albino 
Wistar rats from days 1 to 7 of pregnancy. Values are expressed as mean ± 
SEM; *P<0.05, **P<0.01 when compared to control group (n=6). 
 
 
5.1.2 Anti-implantation activity of montelukast when treated 7-21 days of 
pregnancy 
The LOX inhibitor montelukast elicited significant pre-implantation loss 
at dose levels of 1 mg/kg (p<0.05), 10 mg/kg (p<0.001), 20 mg/kg (p<0.001) 
and the anti-fertility activity, at dose levels of 1 mg/kg (p<0.001), 10 mg/kg 
(p<0.001) and 20 mg/kg (p<0.001), when compared to control group (Table: 6-
9, Figure: 2). 
 
 
 
 
Table 6: Pre-implantation, post-implantation and anti-fertility activity of 
control group (1% w/v CMC 10 ml/kg)    
S.NO
. 
BODY 
WEIGH
T 
NO. OF 
CORPOR
A LUTEA
NO. OF 
IMPLAN
TS 
NO. 
OF 
LITTE
RS 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTATI
ON LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 180 10 8 6 20 25 40 
2 160 14 11 7 21.428 36.36 50 
3 170 9 8 4 11.11 50 55.55 
4 170 12 10 6 16.66 40 50 
5 190 10 8 5 20 37.5 50 
6 160 15 12 8 20 33.33 46.66 
MEA 171.6 11.666 9.5 6 18.199 37.031 48.701 
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N 66 
± 
SEM 
4.773 0.988 0.7188 0.577
4 
1.558 3.347 2.096 
± SD 11.69
0 
2.422 1.761 1.414 3.815 8.199 5.135 
 
 
 
Table 7: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (1 mg/kg) 
S.NO
. 
BODY 
WEIG
HT 
NO. OF 
CORPOR
A LUTEA
NO. OF 
IMPLAN
TS 
NO. 
OF 
LITTE
RS 
% PRE-
IMPLANTAT
ION LOSS 
%  POST-
IMPLANTAT
ION LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 150  11 6 0 45.45 100 100  
2 170 13 8 1 38.46 87.5 92.3076 
3 190 12 9 2 25 77.77 83.33 
4 160 13 0 0 100 0 100 
5 160 12             0 0 100 0 100 
 6 200 11 8 2 27.27 75 81.8181 
MEA
N 
171.6
66 
12 5.16666 0.833
3 
56.03 56.711667 92.90928
3 
± 
SEM 
7.923 0.3651 1.682 0.401
4 
14.233 18.287 3.493 
± SD 19.40
8 
0.8944 4.119 0.983
2 
34.864 44.793 8.555 
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Table 8: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (10 mg/kg) 
S.NO
. 
BODY 
WEIG
HT 
NO. OF 
CORPOR
A LUTEA
NO. OF 
IMPLAN
TS 
NO. 
OF 
LITTE
RS 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTAT
ION LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 150 13 3 1 76.9230 66.6666 92.3076 
2 160 14 0 0 100 0 100 
3 190 12 0 0 100 0 100 
4 200 15 0 0 100 0 100 
5 200 9 0 0 100 0 100 
6 150 14 0 0 100 0 100 
MEA
N 
175 12.833
3 
0.5 0.166
66 
96.15833 11.1111 98.71793
3 
± 
SEM 
9.916 0.8724 0.5000 0.166
7 
3.846 11.111 1.282 
± SD 24.29
0 
2.137 1.225 0.408
2 
9.421 27.217 3.140 
 
 
 
 
Table 9: Pre-implantation, post-implantation and anti-fertility activity of 
montelukast (20 mg/kg) 
S.NO
. 
BODY 
WEIG
HT 
NO. OF 
CORPOR
A LUTEA
NO. OF 
IMPLAN
TS 
NO. OF 
LITTE
RS 
% PRE-
IMPLANTAT
ION LOSS 
% POST-
IMPLANTAT
ION LOSS 
% ANTI-
FERTILI
TY 
ACTIVIT
Y 
1 160 13 0 0 100 0 100 
2 170 11 2 0 81.81 100 100 
3 200 11 2 0 81.81 100 100 
4 150 12 0 0 100 0 100 
5 180 11 0 0 100 0 100 
6 200 13 0 0 100 0 100 
MEA
N 
176.6
66 
11.833
3 
0.666 0 93.93667 33.333 100 
± 
SEM 
8.433 0.4014 0.4216 0 3.835 21.082 0 
± SD 20.65
6 
0.9832 1.033 0 9.393 51.640 0 
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Table 10: Shows anti-implantation activity of montelukast treated for 7-21 days 
of pregnancy at different dose levels of 1, 10 and 20 mg/kg body weight  
S.N
O. 
TREATME
NT 
PRE-
IMPLANTATIO
N LOSS (  mean 
± SEM ) 
POST-
IMPLANTATIO
N LOSS ( mean 
± SEM ) 
ANTI-
FERTILITY 
ACTIVITY  
( mean ± SEM ) 
 
1 Control 18.199 ± 1.558 37.031 ± 3.347 48.701 ± 2.096 
 
2 Monteluk
ast 
 (1 mg/kg) 
56.03 ± 14.233* 56.711667 ± 
18.287 
92.909283 ± 
3.493*** 
 
3 Monteluk
ast 
(10 
mg/kg) 
96.15833 ± 
3.846*** 
11.1111 ± 11.111 98.717933 ± 
1.282*** 
4 Monteluk
ast 
(20 
mg/kg) 
93.93667± 
3.835*** 
33.333 ± 21.082 100 ± 000*** 
 
n=6; The values are expressed as mean ± SEM; *P< 0.05, ***P<0.001 when 
compared to control groups (One way ANNOVA followed by Tukey’s multiple 
comparison Test). 
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Figure 2:  Pre- and post-implantation loss (%) and anti-fertility activity (%) of 
montelukast when administered orally at various dose levels to female albino 
Wistar rats from days 7 to 21 of pregnancy. Values are expressed as mean ± 
SEM; *P<0.05, ***P<0.001 when compared to control group (n=6). 
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          CHAPTER-6 
DISCUSSION 
India possess 16 percent of the world's population on 2.4 percent of the 
globe's land area. Thus the most important problem India facing today is the 
size and growth of its population. The census 2001 has shown that the 
population of India was 102.70 crores as on 1st March 2001. In the 50 years 
since 1951 the population of the country has increased from 36.11 crores to 
102.70 crores. India’s population is growing very fast the pressure of numbers 
on the natural resources of the country is bound to grow. The density of 
population has increased from 117 persons per sq.km in 1951 to 324 persons in 
2001, which may worsen the already very poor social and demographic 
indicators in this country. 140 
Arachidonic acid is metabolized mainly by lipoxygenases (LOX, which 
includes 5-LOX, 12-LOX, and 15-LOX) and cyclooxygenase (COX, which 
includes COX-1, COX2). 5-lipoxygenase is the first committed enzyme in the 
LOX pathway leading to the production of 5-hydroperoxyeicosatetraenoic acid 
(5-HPETE) with the subsequent production of 5-HETE and leukotrienes, which 
includes LTA4, LTB4, LTC4, LTD4, and LTE4.141 Targeting upstream 
enzymes affects multiple downstream pathways, and may produce adverse 
effects by disrupting the balance between different AA-metabolizing pathways. 
It may be more advisable to target downstream enzymes or receptors.142 
The lipoxygenase products (leukotrienes) have been demonstrated in 
many mammalian tissues including humans.10 Leukotrienes are involved in 
various stages of reproduction including ovulation,11, 12, 13, 14 implantation,17, 
143,144
 decidulation,21 parturition.19 
Pakrasi et al., (1985) reported that the presence of the lipoxygenase 
pathways in the pre-implantation rabbit uterus and blastocyst, their differential 
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operation in various compartments of the uterus on various days of early 
pregnancy suggests an integrated role for these mediators in embryo-uterine 
interaction during implantation.17 Leukotrienes could be important for uterine 
preparation for implantation and/or implantation per se.143  Lipoxygenase 
product might have a role in implantation.144 
Mouse and human spermatozoa require cysteinyl leukotriene activity for 
both fertilization and oocyte penetration.18 Lipoxygenase metabolites may be 
involved in human parturition. Role for 5-LOX and FLAP in the control of 
parturition at term, and also suggest an involvement earlier in pregnancy.19 LTs 
are required for the induction and progression of decidualization.21 
If these role of leukotriene in normal implantation are blocked it may 
negatively affect the implantation. Based on these hypothesis we have selected 
montelukast, a cysteinyl leukotriene receptor antagonists for evaluating anti-
fertility activity in albino Wistar rats. 
Montelukast sodium is used primarily for the treatment of asthma, 
Chronic Obstructive Pulmonary Disease (COPD) and in relieving the 
symptoms of allergic rhinitis. It is an orally active compound that binds with 
high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits 
physiological actions of LTD4 at the CystLT1 receptor.145 
In the present study the oral administration of leukotrienes receptor 
antagonist montelukast was tested for anti-fertility properties in three doses of 
1mg/kg (conversion from adult human dose to animal dose), 10mg/kg and 20 
mg/kg body weight of rats146, 147 for 1 to 7 days and 7 to 21 days of pregnancy.  
Days 1-7 of treatment were selected because they cover the entire 
implantation period.  Days 1-3 are the days of the preparation of the 
endometrium for the implantation of the blastocyst, when the uterine blood 
flow increases rapidly due to increased permeation of endometrial 
capillaries.148 Afternoon of day 4 is believed to be the time of the "estrogen 
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surge", which might be responsible for implantation on day 5. Days 6-7 are 
very early stages of post- implantation period.149  Days 7-21 is post-
implantation period.  
In 1 to 7 days the rats treated with montelukast 10 mg/kg showed 
significant (p<0.05) % anti-fertility activity when compared to control group. 
The animal’s treated with montelukast 20 mg/kg showed significant (p<0.01) 
% pre-implantation loss and     % anti-fertility activity when compared to 
control group (Table: 1-5, Figure: 1). In this study treatment of 1-7 days, 
montelukast showed significant anti-fertility activity in a dose dependent 
manner. 
In 7 to 21 days the rats treated with montelukast 1 mg/kg showed 
significant (p<0.05) % pre-implantation loss when compared to control group. 
The animals treated with montelukast 10 mg/kg, 20 mg/kg showed significant 
(p<0.001) % pre-implantation loss when compared to control group. The 
experimental group treated with montelukast  1 mg/kg, 10 mg/kg, 20 mg/kg 
showed significant (p<0.001) % anti-fertility activity when compared to control 
group (Table: 6-10, Figure: 2). In this study treatment of 7-21 days montelukast 
showed significant anti-fertility activity in a dose dependent manner. 
Pakrasi, (1997) have reported that a selective inhibitor of 5-lipoxygenase 
enzyme may not impair the implantation in mice indicating a doubt about the 
involvement of 5-lipoxygenase products in implantation.11 But in our study 
results showed dose dependent anti-implantation activity of montelukast a 
cystenyl leukotrienes receptor antagonist in female albino Wistar rats. 
If an ideal contraceptive is available, that would be 100% effective, safe 
and easy to use and its effect would be reversible.1 We showed that the LOX-
inhibitor montelukast 20 mg/kg achieved 100% anti-fertility activity in both 1-
7 days and 7-21 days study treatment.  
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Our study revealed that montelukast satisfying the one of the criteria of 
ideal contraceptive. Our results also confirm that leukotriene are involved in 
the process of implantation. We interpret our results as confirmation that 
leukotrienes produced in the endometrium are involved in implantation in the 
rat and that the drug we administered act at the endometrial level. To confirm 
this interpretation it would be essential to document that the treatments did not 
cause endocrine changes that interfere with implantation of pregnancy. For 
instance, an increase in oestradiol would accelerate egg transport through the 
oviduct and reduce the number of implanted embryos. Inhibition of prolactin 
secretion and subsequent luteolysis with decreased progesterone production 
would also cause pre and post implantation loss. An additional approach could 
consist of demonstrating that exogenous progesterone does not reverse the 
action of drugs. 
We consider that strength of our anti-fertility study includes that results 
were obtained by direct observation. Anti-implantation research is a promising 
field of WHO contraceptive research and development programmes. Since we 
studied the anti-implantation activity of montelukast, it may add good scientific 
knowledge to the contraceptive research. 
Our study suggested that montelukast can be used as an anti-fertility 
agent, since it produced 100% anti-fertility activity. However further studies 
needed to establish the safety and efficacy of montelukast in pregnant animals. 
If the efficacy and safety is established in animals, we can further proceed to 
establish its efficacy and safety in humans by suitable clinical trials. 
Our study also suggested that the cysteinyl leukotriene receptor 
antagonist montelukast can be avoided in pregnant women and the women with 
reproductive age groups. It is also suggested that proper pharmacovigilance 
studies can be carried out in montelukast to establish its safety in pregnant 
women and proper warning can be done on the label. 
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       CHAPTER-7 
CONCLUSION 
Montelukast, a cysteinyl leukotrienes receptor antagonist posses 100% 
anti-implantation activity in albino Wistar rats. Our results indirectly confirms 
the involment of leukotrienes in implantation. Our results suggested that 
montelukast can be used as an anti-fertility agent after confirming its safety and 
efficacy in humans. 
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